Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia

Clinical Nutrition

Volumn 33, Issue 3, 2014, Pages 448-458

  Ham, Daniel J ^a   Murphy, Kate T ^a   Chee, Annabel ^a   Lynch, Gordon S ^a   Koopman, René ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

C 26 tumor bearing mice; Inflammation; Muscle function; Muscle mass

Indexed keywords

ALANINE; ATROGIN 1; CITRULLINE; GLYCINE; INTERLEUKIN 6; MESSENGER RNA; MUSCLE RING FINGER PROTEIN; PROTEIN BNIP3; RING FINGER PROTEIN; UNCLASSIFIED DRUG; FATTY ACID; GAMMA INTERFERON; INTERLEUKIN 1BETA; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY MASS; CACHEXIA; CANCER CELL CULTURE; CD2F1 MOUSE; CONTROLLED STUDY; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE MASS; MYOSITIS; NONHUMAN; OXIDATIVE STRESS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WESTERN BLOTTING; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ADIPOSE TISSUE; ANIMALS; BODY MASS INDEX; CACHEXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FATTY ACIDS, NONESTERIFIED; GLYCINE; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICE; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899659374     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2013.06.013     Document Type: Article

References (29)

1. Murphy K.T., Chee A., Trieu J., Naim T., Lynch G.S. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Disease Models Mech 2012, 5(4):533-545.
2. Fearon K., Strasser F., Anker S.D., Bosaeus I., Bruera E., Fainsinger R.L., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011, 12(5):489-495.
3. Lynch G.S., Schertzer J.D., Ryall J.G. Therapeutic approaches for muscle wasting disorders. Pharmacol Ther 2007, 113(3):461-487.
4. Tranmer J.E., Heyland D., Dudgeon D., Groll D., Squires-Graham M., Coulson K. Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manage 2003, 25(5):420-429.
5. Argilés J.M., Busquets S., Lopez-Soriano F.J. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol 2011, 668(Suppl 1):S81-S86.
6. Koopman R. Dietary protein and exercise training in ageing. Proc Nutr Soc 2011, 70(1):104-113.
7. Peters S.J., van Helvoort A., Kegler D., Argiles J.M., Luiking Y.C., Laviano A., et al. Dose-dependent effects of leucine supplementation on preservation of muscle mass in cancer cachectic mice. Oncol Rep 2011, 26(1):247-254.
8. Ascher E., Hanson J.N., Cheng W., Hingorani A., Scheinman M. Glycine preserves function and decreases necrosis in skeletal muscle undergoing ischemia and reperfusion injury. Surgery 2001, 129(2):231-235.
9. Zhong Z., Wheeler M.D., Li X., Froh M., Schemmer P., Yin M., et al. L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent. Curr Opin Clin Nutr Metab Care 2003, 6(2):229-240.
10. Zachwieja J.J., Witt T.L., Yarasheski K.E. Intravenous glutamine does not stimulate mixed muscle protein synthesis in healthy young men and women. Metabolism 2000, 49(12):1555-1560.
11. De Luca A., Pierno S., Liantonio A., Cetrone M., Camerino C., Fraysse B., et al. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther 2003, 304(1):453-463.
12. Koopman R., Manders R.J., Jonkers R.A., Hul G.B., Kuipers H., van Loon L.J. Intramyocellular lipid and glycogen content are reduced following resistance exercise in untrained healthy males. Eur J Appl Physiol 2006, 96(5):525-534.
13. Bindokas V.P., Jordan J., Lee C.C., Miller R.J. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J Neurosci Official J Soc Neurosci 1996, 16(4):1324-1336.
14. Roth E. Immune and cell modulation by amino acids. Clin Nutr 2007, 26(5):535-544.
15. Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012, 336(6084):1040-1044.
16. Rose M.L., Madren J., Bunzendahl H., Thurman R.G. Dietary glycine inhibits the growth of B16 melanoma tumors in mice. Carcinogenesis 1999, 20(5):793-798.
17. Yamashina S., Konno A., Wheeler M.D., Rusyn I., Rusyn E.V., Cox A.D., et al. Endothelial cells contain a glycine-gated chloride channel. Nutr Cancer 2001, 40(2):197-204.
18. Murphy K.T., Lynch G.S. Editorial update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 2012, 17(1):5-9.
19. Guo C.B., Zhang W., Ma D.Q., Zhang K.H., Huang J.Q. Hand grip strength: an indicator of nutritional state and the mix of postoperative complications in patients with oral and maxillofacial cancers. Br J Oral Maxillofacial Surg 1996, 34(4):325-327.
20. Yamamoto N., Kawamura I., Nishigaki F., Tsujimoto S., Naoe Y., Inami M., et al. Effect of FR143430, a novel cytokine suppressive agent, on adenocarcinoma colon26-induced cachexia in mice. Anticancer Res 1998, 18(1A):139-144.
21. Kosmidou I., Vassilakopoulos T., Xagorari A., Zakynthinos S., Papapetropoulos A., Roussos C. Production of interleukin-6 by skeletal myotubes: role of reactive oxygen species. Am J Respir Cell Mol Biol 2002, 26(5):587-593.
22. Zhang C., Li Y., Wu Y., Wang L., Wang X., Du J. Interleukin-6/signal transducer and activator of transcription 3 (STAT3) pathway is essential for macrophage infiltration and myoblast proliferation during muscle regeneration. J Biol Chem 2013, 288(3):1489-1499.
23. McClung J.M., Judge A.R., Powers S.K., Yan Z. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol 2010, 298(3):C542-C549.
24. Gomes-Marcondes M.C., Tisdale M.J. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett 2002, 180(1):69-74.
25. Rutten E.P., Engelen M.P., Schols A.M., Deutz N.E. Skeletal muscle glutamate metabolism in health and disease: state of the art. Curr Opin Clin Nutr Metab Care 2005, 8(1):41-51.
26. Grumati P., Bonaldo P. Autophagy in skeletal muscle homeostasis and in muscular dystrophies. Cells 2012, 1:325-345.
27. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117(3):399-412.
28. Lagirand-Cantaloube J., Offner N., Csibi A., Leibovitch M.P., Batonnet-Pichon S., Tintignac L.A., et al. The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J 2008, 27(8):1266-1276.
29. Schakman O., Dehoux M., Bouchuari S., Delaere S., Lause P., Decroly N., et al. Role of IGF-I and the TNFalpha/NF-kappaB pathway in the induction of muscle atrogenes by acute inflammation. Am J Physiol Endocrinol Metab 2012, 303(6):E729-E739.